ReviewMolecular medicine reports2026
Role of the circadian rhythm in squamous cell carcinoma: From molecular mechanism to therapy (Review).
Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Squamous cell carcinoma (SCC) comprises a heterogeneous group of malignancies with distinct molecular characteristics, clinical behavior and therapeutic responses, highlighting the need for personalized treatment strategies. Circadian rhythms regulate fundamental physiological processes, including cell proliferation, metabolism, DNA repair and immune function, and emerging evidence suggests that circadian regulation may influence pathways relevant to SCC biology and treatment response. This review summarizes current knowledge on the role of circadian regulation in SCC, with particular emphasis on lung SCC, focusing on core clock genes, their interactions with oncogenic and immune‑related pathways, and their therapeutic implications. We discuss current evidence supporting chronotherapy as a potential component of personalized SCC treatment while addressing important limitations, including the predominance of preclinical studies, limited SCC‑specific clinical evidence and extrapolation from other tumor types. Finally, we outline key research priorities for translating circadian biology into clinical SCC management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.